An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This is a two-part, randomized, double-blind, placebo-controlled study in which VTP-43742
will be administered to normal healthy volunteers (NHV) and to moderate to severe psoriatic
patients, both in sequential ascending dose panels.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Vitae Pharmaceuticals Inc., an Allergan affiliate Vitae Pharmaceuticals, Inc.